Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Liabilities and Shareholders Equity (2016 - 2025)

Fortress Biotech has reported Liabilities and Shareholders Equity over the past 13 years, most recently at $185.5 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $185.5 million for Q4 2025, up 28.65% from a year ago — trailing twelve months through Dec 2025 was $704.9 million (up 21.2% YoY), and the annual figure for FY2025 was $185.5 million, up 28.65%.
  • Liabilities and Shareholders Equity for Q4 2025 was $185.5 million at Fortress Biotech, up from $181.4 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for FBIO hit a ceiling of $418.2 million in Q2 2021 and a floor of $127.1 million in Q3 2024.
  • Median Liabilities and Shareholders Equity over the past 5 years was $183.5 million (2025), compared with a mean of $252.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 70.94% in 2021 and later crashed 53.47% in 2023.
  • Fortress Biotech's Liabilities and Shareholders Equity stood at $396.5 million in 2021, then fell by 25.78% to $294.3 million in 2022, then plummeted by 43.08% to $167.5 million in 2023, then decreased by 13.91% to $144.2 million in 2024, then increased by 28.65% to $185.5 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $185.5 million (Q4 2025), $181.4 million (Q3 2025), and $159.9 million (Q2 2025) per Business Quant data.